Dermatology
Latest news
109 articles · 20 / page
Navigating Scrotal Health: A Comprehensive Guide to Lymphedema and Excessive Sweating
This article provides an in-depth exploration of scrotal lymphedema and hyperhidrosis, detailing their physiological causes, clinical symptoms, and the latest management strategies for both patients and healthcare providers.
Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models
A pilot randomized controlled trial and translational study demonstrate that Sopoongsan (SPS) effectively reduces chronic upper body pruritus in atopic and seborrheic dermatitis by inhibiting STAT1-mediated inflammatory pathways, offering a
Topical Botanical Solution Cinainu Shows Sustained Efficacy and Safety in Paediatric Alopecia Areata: Insights from the RAAINBOW Trial
The RAAINBOW phase II/III trial demonstrates that Cinainu, a topical botanical solution, significantly improves hair regrowth and quality of life in paediatric patients with moderate-to-severe alopecia areata, offering a well-tolerated alte
Targeted Tolerance Induction in Pemphigus Vulgaris: A Synthesis of Phase I Clinical and Preclinical Evidence for TPM203 Nanoparticles
This review evaluates TPM203, a novel nanoparticle-based therapy for Pemphigus Vulgaris, detailing its safety profile, rapid pharmacokinetics, and ability to modulate regulatory T-cell and memory B-cell populations to induce immune toleranc
Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program
This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients
Breaking the Wall: Can Intermittent Chemotherapy Overcome Primary Checkpoint Inhibitor Resistance in Metastatic Melanoma?
The multicentre phase II PROMIT trial demonstrates that intermittent dacarbazine can sensitize BRAF wildtype metastatic melanoma patients with primary ICI resistance to subsequent ICI rechallenge, yielding an 18% objective response rate and
Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment
A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s
Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa
The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therap
Precision Dosing of Secukinumab in Hidradenitis Suppurativa: Insights from the SUNSHINE and SUNRISE Pooled Pharmacokinetic Analysis
This review synthesizes the 52-week pooled results from two Phase 3 trials, detailing the pharmacokinetics, safety, and biomarker responses of secukinumab in moderate-to-severe hidradenitis suppurativa.
Targeting CXCR1/2 Ligands: Eltrekibart Demonstrates Clinical Potential in Phase 2 Hidradenitis Suppurativa Trial
A Phase 2 trial of eltrekibart, a novel monoclonal antibody targeting CXCR1/2 ligands, suggests high clinical efficacy in hidradenitis suppurativa. While frequentist analysis was neutral, Bayesian augmented models showed a 99.9% probability
Saturated Saline Immersion: A Novel and Noninvasive Approach for Refractory Plantar Warts
This report examines a clinical trial using 30-minute daily saturated saline immersion to treat refractory plantar warts, achieving an 88.2% complete remission rate without pain or recurrence.
Long-Term Efficacy and Safety of Apremilast in Moderate to Severe Genital Psoriasis: The 32-Week DISCREET Extension Data
The Phase 3 DISCREET trial demonstrates that apremilast provides sustained clinical efficacy and quality-of-life improvements for patients with moderate to severe genital psoriasis over 32 weeks, offering a viable oral alternative for a tra
Beyond Th2: Single-Dose Aletekitug Targets IL-18 to Deliver Sustained Clinical and Molecular Remission in Atopic Dermatitis
A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 i
Bathing Frequency and Eczema Severity: Analysis of the Eczema Bathing Citizen Science Randomized Controlled Trial
A pragmatic RCT comparing weekly versus daily bathing in 438 eczema patients found no significant difference in symptom severity, supporting patient autonomy in choosing hygiene routines.
Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial
A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre
Antenatal Prebiotic Supplementation Fails to Prevent Atopic Dermatitis in High-Risk Infants: Insights from the PREGRALL Trial
The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c
Unorthodox JAK Inhibitor Dosing in Pediatric Moderate-to-Severe Alopecia Areata: A Comparative Evaluation of Tofacitinib and Baricitinib
This study of 100 pediatric patients with moderate-to-severe alopecia areata demonstrates that unorthodox dosing regimens of tofacitinib and baricitinib provide comparable efficacy and high tolerability over 24 weeks.
Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case-Cohort Analysis of Clonal Inflammation
MDS and CMML can present with lupuslike manifestations that represent a distinct entity of clonal inflammation rather than idiopathic autoimmunity. This study highlights the need for clone-directed therapies over standard lupus treatments.
Validating the Patient’s Voice in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis of Patient-Reported Outcome Measures
This systematic review and meta-analysis evaluates 15 HS-specific PROMs using the COSMIN framework, identifying 7 recommended instruments and highlighting the superior psychometric performance of HiSQOL-17 while uncovering significant gaps
Browse by specialty
Open language-specific specialty feeds and department pages.